secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001654954-23-014355
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences Q3 net loss $3.1M; FDA De Novo review ongoing
-----------------------------------------------------------------

- Net loss $3.1M ($0.40/share) vs $3.4M ($1.09/share) in Q3 2022; operating expense $3.1M.
- Cash $3.3M at Sept 30; raised $1.2M via ATM equity facility during Q3.
- TAEUS De Novo submission under substantive FDA review; clinical data showed 95% sensitivity.
- Achieved 70 issued patents globally; targeting first European commercial orders near-term.
- Presented at major liver disease conferences; expects MASLD treatment approvals in early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495423014355/0001654954-23-014355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495423014355/ndra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-014355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer